Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years-of-age or older.~* Stable, heterosexual relationship for at least 6 months.~* A history of erectile dysfunction (ED) for at least 6 months~Exclusion Criteria:~* Any underlying cardiovascular condition, including unstable angina pectoris~* History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1~* Uncontrolled atrial fibrillation / flutter at screening~* History of congenital QT prolongation~* History of surgical prostatectomy due to prostate cancer~* Hereditary degenerative retinal disorders~* History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision~* Presence of penile anatomical abnormalities~* Spinal cord injury~* Resting or postural hypotension or hypertension~* Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha-blockers, HIV (Human immunodeficiency virus) protease inhibitors, itraconazole or ketoconazole, and clarithromycin and erythromycin.~* Subjects taking medication known to prolong QT interval, such as Type Ia and Type 3 anti-arrhythmics.~* Subjects who have been confirmed with phenylketonuria (PKU).~* Use of any treatment for ED within 7 days of Visit 1.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil ODT (STAXYN, BAY38-9456) (Type: EXPERIMENTAL): Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).